Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots

Area of Science:

• Immunology
• Pathophysiology
• Infectious Diseases

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, presents a significant global health challenge with unclear pathophysiology.
• A high prevalence of thromboembolic events in COVID-19 patients suggests a link to prothrombotic mechanisms.
• Similarities observed between COVID-19 and antiphospholipid syndrome (APS), an autoimmune prothrombotic disorder, warrant further investigation.

Purpose of the Study:

• To explore the clinicopathological similarities between COVID-19 and APS.
• To investigate the potential mechanisms, such as molecular mimicry and endothelial dysfunction, contributing to thrombogenesis in COVID-19.
• To discuss potential therapeutic targets for COVID-19 informed by the antiphospholipid model.

Main Methods:

• Review of existing literature on COVID-19 pathophysiology and thromboembolic events.
• Comparison of clinical and pathological features of COVID-19 with those of APS.
• Analysis of proposed mechanisms for thrombogenesis in APS and their potential relevance to COVID-19.

Main Results:

• COVID-19 exhibits significant clinicopathological overlap with APS, particularly concerning thromboembolic phenomena.
• Antiphospholipid antibodies (aPLs) have been detected in COVID-19 patients, suggesting a potential autoimmune component.
• Molecular mimicry and endothelial dysfunction are plausible mechanisms linking SARS-CoV-2 infection to prothrombotic states.

Conclusions:

• COVID-19 shares key features with APS, suggesting a potential role for antiphospholipid antibodies and related mechanisms.
• Understanding these similarities may guide the development of novel therapeutic strategies for managing thrombotic complications in COVID-19.
• Further research into the antiphospholipid model could offer new avenues for treating severe COVID-19.